Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes.

Familial cancer - 1 Dec 2013

Sie Aisha S, Prins Judith B, Spruijt Liesbeth, Kets C Marleen, Hoogerbrugge Nicoline

Abstract excerpt

DNA-testing for BRCA1/2 or Lynch syndrome is possible from the age of 18 years, although surveillance usually starts at 25. Some patients regret their decision of testing before age 25. This retrospective study evaluates whether the testing age should be above 25 years to prevent adverse effects such as regret or decisional conflict, by determining the percentage and characteristics of patients reporting these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Decision Making
Share to DNA Repair Enzymes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Counseling

Share to Neoplastic Syndromes, Hereditary

Share to Quality of Life

Share to Survival Rate

Source

Identifiers

PMID: 23604858
DOI: 10.1007/s10689-013-9644-9

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes.PMID 23604858Read ↗

A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25.Semantic proximity Read ↗

Cancer risk management decision making for BRCA+ women.Semantic proximity Read ↗

Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.Semantic proximity Read ↗

In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.Semantic proximity Read ↗

"It's not if I get cancer, it's when I get cancer": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk.Semantic proximity Read ↗

"I wish that there was more info": characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants.Semantic proximity Read ↗

Life trajectories, genetic testing, and risk reduction decisions in 18-39 year old women at risk for hereditary breast and ovarian cancer.Semantic proximity Read ↗

“I need to know if I’m going to die young”: Adolescent and young adult experiences of genetic testing for Li–Fraumeni syndromeSemantic proximity Read ↗

Previvors' Uncertainty Management Strategies for Hereditary Breast and Ovarian Cancer.Semantic proximity Read ↗

One Year Follow-Up of Women Opting for Presymptomatic Testing for BRCA1 and BRCA2: Emotional Impact of the Test Outcome and Decisions on Risk Management (Surveillance or Prophylactic Surgery)Semantic proximity Read ↗

Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant.Semantic proximity Read ↗

How Should Decision Aids Be Used During Counseling to Help Patients Who Are "Genetically at Risk"?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.